课题基金 / 基金详情

MDCT Quantification of hepatic tumor viability for assessment of cancer therapy

MDCT Quantification of hepatic tumor viability for assessment of cancer therapy
MDCT 量化肝肿瘤活力以评估癌症治疗
批准号:
8782327
负责人:
Wenli Cai
金额:
$22.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-16 至 2016-02-29

项目摘要

项目成果

Wenli Cai的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤(超过80%),是全球第三大常见癌症死亡原因。增强多期多层螺旋CT(MDCT)是诊断肝脏恶性肿瘤的常规影像检查方法。在单期(主要是门静脉期)MDCT图像上测量的肿瘤大小的变化通常用于评估肿瘤对治疗的反应。在过去的十年里,随着靶向癌症治疗(如抗血管生成治疗)的出现,晚期肝癌的临床治疗结果得到了显著的改善。然而,由于治疗机制的不同,靶向治疗的肿瘤测量不一定准确地反映由于存在坏死而导致的存活肿瘤大小的变化。因此,仅用肿瘤大小来评估肿瘤反应可能不足以评估靶向治疗时对像肝癌这样的肿瘤的治疗反应。我们建议开发一种创新的定量成像生物标记物,表示为肝脏肿瘤生存能力(HTV),而不是仅使用肿瘤大小来评估靶向治疗,而是使用多时相肝脏MDCT图像来量化接受靶向治疗的肝细胞癌患者的活体和坏死性肿瘤组织以及肝脏和肿瘤的大小。该项目将建立在现有的定量成像分析技术的基础上 马萨诸塞州综合医院(MGH)的3D成像实验室。它将利用co-PI为肝脏和肝脏肿瘤开发的分类和分割算法,该算法通过对多期MDCT图像的时间-强度曲线(TIC)的模式分析来对存活/坏死的肿瘤区域进行分类。项目合作者包括麻省理工学院癌症中心专门从事肝癌靶向治疗(特别是抗血管生成治疗)的肿瘤学家,以及麻省理工学院3D成像实验室专门从事定量成像分析的成像科学家。项目的具体目标是:(1)HTV生物标记物的开发:我们将在云计算平台上开发HTV生物标记物的原型,包括HTV-Server和HTV-Client,HTV-Server是一个自动化的HTV后处理管道,用于对多期MDCT图像中的肝脏、肿瘤和存活/坏死肿瘤区域进行注册、分类和分割,以及HTV-Client是一个基于网络的用户界面,用于HTV量化的交互式可视化、定量分析和护理点数据访问。(2)HTV生物标志物的评估:我们将进行一项临床研究,通过在MGH癌症中心对50例接受抗血管生成治疗的晚期肝癌患者评估所提出的HTV生物标志物在肿瘤进展预后和治疗反应方面的临床表现。(3)项目第二阶段计划:我们将建立公司流程,以满足FDA对项目第二阶段产品的翻译和验证规定。我们的行业合作伙伴(TeraRecon Inc.、Intrasense)已表现出对授权或购买拟议技术的高度兴趣,以将其集成到他们的医疗成像工作站中。
英文摘要
DESCRIPTION (provided by applicant): Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy (more than 80%) and the third most common cause of death from cancer worldwide. Contrast-enhanced multi-phase multi-detector CT (MDCT) is a routine imaging modality for patients diagnosed with hepatic malignancy. The change of tumor size measured on single-phase (mostly portal-venous phase) MDCT images is used routinely for assessment of tumor response to treatment. With the advent of targeted cancer therapies (such as antiangiogenic treatment) over the past decade, the clinical outcome in the treatment of advanced HCC has been significantly improved. However, because of the difference in the mechanisms of therapies, measurement of tumors treated with targeted therapy does not necessarily accurately represent the change in viable tumor size due to the presence of necrosis. Therefore, the assessment of tumor response using tumor size alone may inadequately evaluate the treatment response for tumors like HCC when treated with targeted therapies. Instead of using tumor size alone to assess targeted therapies, we propose to develop an innovative quantitative imaging biomarker, denoted as hepatic tumor viability (HTV), using multi-phase hepatic MDCT images for quantification of viable and necrotic tumor tissues in addition to the size of liver and tumors for HCC patients treated with targeted therapies. This project will be built upon existing technologies for quantitative imaging analysis developed at the 3D Imaging Lab at the Massachusetts General Hospital (MGH). It will make use of the classification and segmentation algorithms developed by the co-PI for liver and liver tumors, which classifies viable/necrotic tumor regions by using pattern analysis of time-intensity curve (TIC) in multi-phase MDCT images. Project collaborators include oncologists specialized in targeted therapy for HCC (particular on antiangiogenic treatment) at the MGH Cancer Center, and imaging scientists specializing in quantitative imaging analysis from the 3D Imaging Lab at the MGH. The specific aims of the project are: (1) Development of HTV biomarker: We will develop the prototype HTV biomarker on a cloud-computing platform, including HTV-Server that is an automated HTV post-processing pipeline for the registration, classification and segmentation of liver, tumors and viable/necrotic tumor regions in multi-phase MDCT images, and HTV-Client that is a web-based user interface for interactive visualization, quantitative analysis, and point-of-care data access for the HTV quantification. (2) Evaluation of HTV biomarker: We will conduct a clinical study to evaluate the clinical performance of the proposed HTV biomarker in the prognosis of tumor progress and treatment response by using 50 advanced HCC cases treated with antiangiogenic therapies at the MGH Cancer Center. (3) Plan of project Phase II: We will establish the company processes to meet FDA regulations for translation and validation of the product in Phase II of the project. Our industrial collaborators (TeraRecon Inc, Intrasense) have shown their high level of interests in licensing or purchasing the proposed technology to integrate it into their medical imaging workstations.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Iterative mesh transformation for 3D segmentation of livers with cancers in CT images.
用于 CT 图像中患有癌症的肝脏 3D 分割的迭代网格变换。
DOI: 10.1016/j.compmedimag.2015.01.006
发表时间: 2015
期刊: Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
影响因子: --
作者: [Lu,Difei, Wu,Yin, Harris,Gordon, Cai,Wenli]
通讯作者: Cai,Wenli
Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses
  • 批准号:
    9762866
  • 项目类别:
  • 资助金额:
    $71.94万
  • 财政年份:
    2015
  • 负责人:
    Wenli Cai
  • 依托单位:
海外基金